[PMC free content] [PubMed] [Google Scholar] 34

[PMC free content] [PubMed] [Google Scholar] 34. J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N, Navarro B, Ichim TE, Urquhart B, Min W. Silencing IDO in dendritic cells: a book method of enhance cancers immunotherapy within a murine breasts cancer tumor model. Int J Cancers. 2013;132:967C977. [PubMed] [Google Scholar] 16. Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, Individuals GE. Results from the initial stage 1 scientific trial from the HER-2/neu peptide (GP2) GSK2656157 vaccine in disease-free breasts cancer sufferers: USA Military Cancer tumor Institute Clinical Studies Group Research I-04. Cancers. 2010;116:292C301. [PubMed] [Google Scholar] 17. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumour-associated carbohydrate antigens in breasts cancer. Breast Cancer tumor Res. 2010;12:204. [PMC free of charge content] [PubMed] [Google Scholar] 18. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Aged LJ, Caballero O, Neville AM. Multiple cancers/testis antigens are expressed in hormone-receptor detrimental and high-grade breasts malignancies preferentially. PLoS One. 2011;6:e17876. [PMC free of charge content] [PubMed] [Google Scholar] 19. Chornoguz O, Gapeev A, O’Neill MC, Ostrand-Rosenberg S. Main histocompatibility complex course II+ invariant string negative breasts cancer tumor cells present exclusive peptides that activate tumor-specific T cells from breasts cancer sufferers. Mol Cell Proteomics. 2012;11:1457C1467. [PMC free of charge content] [PubMed] [Google Scholar] 20. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Hyperlink J, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in sufferers with metastatic breasts cancer tumor. J Clin Oncol. 2009;27:4685C4692. [PMC free of charge content] [PubMed] [Google Scholar] 21. Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson WE, 3rd, Kaumaya PT. Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes excellent antineoplastic results in transplantable and transgenic mouse types of individual breasts cancer tumor. Oncoimmunology. 2012;1:1004C1016. [PMC free of charge content] [PubMed] [Google Scholar] 22. Hamai A, Duperrier-Amouriaux K, Pignon P, Raimbaud I, Memeo L, Colarossi C, Canzonieri V, Perin T, Classe JM, Campone M, Jezequel P, Campion L, Ayyoub M, Valmori D. Antibody replies to NY-ESO-1 in principal breasts cancer recognize a subtype focus on for immunotherapy. PLoS One. 2011;6:e21129. [PMC free of charge content] [PubMed] [Google Scholar] 23. Mls D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK. Stage III multicenter scientific trial from the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breasts cancer tumor. Oncologist. Rabbit Polyclonal to OR10H1 2011;16:1092C1100. [PMC free of charge content] [PubMed] [Google Scholar] 24. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Individuals GE. Clinical trial outcomes from the HER-2/neu (E75) vaccine to avoid breasts cancer tumor recurrence in high-risk sufferers: from US Armed forces Cancer tumor Institute Clinical Studies Group Research I-01 and I-02. Cancers. 2012;118:2594C2602. [PMC free of charge content] [PubMed] [Google Scholar] 25. Mulens V, de la Torre A, Marinello P, Rodriguez R, Cardoso J, Diaz R, O’Farrill M, Macias A, Viada C, Saurez G, Carr A, Crombet T, Mazorra Z, et al. Immunogenicity and basic safety of the NeuGcGM3 based cancer tumor vaccine: outcomes from a managed research in metastatic breasts cancer sufferers. Hum Vaccin. 2010;6 [PubMed] [Google Scholar] 26. Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Individuals GE. Clinical and immunologic replies of HLA-A3+ breasts cancer sufferers vaccinated using the HER2/neu-derived peptide vaccine, E75, GSK2656157 within a stage I/II scientific trial. J Am Coll Surg. 2010;210:140C147. [PubMed] GSK2656157 [Google Scholar] 27. Silina K, Zayakin P, Kalnina Z, Ivanova L, I Meistere, Endzelins E, Abols A, Stengrevics A, Leja M, Ducena K, Kozirovskis V, Series A. Sperm-associated antigens as goals for cancers immunotherapy: expression design and humoral immune system response in cancers sufferers. J Immunother. 2011;34:28C44. [PubMed] [Google Scholar] 28. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, HK Lyerly, et al. CSPG4 proteins as a fresh focus on for the antibody-based immunotherapy of triple-negative breasts cancer tumor. J Natl Cancers Inst. 2010;102:1496C1512. [PMC free GSK2656157 of charge content] [PubMed] [Google Scholar] 29. Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria.